vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and AMICUS THERAPEUTICS, INC. (FOLD). Click either name above to swap in a different company.
AMICUS THERAPEUTICS, INC. is the larger business by last-quarter revenue ($185.2M vs $112.4M, roughly 1.6× BYLINE BANCORP, INC.). BYLINE BANCORP, INC. runs the higher net margin — 33.4% vs 0.9%, a 32.5% gap on every dollar of revenue. On growth, AMICUS THERAPEUTICS, INC. posted the faster year-over-year revenue change (23.7% vs 9.0%). Over the past eight quarters, AMICUS THERAPEUTICS, INC.'s revenue compounded faster (29.5% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
BY vs FOLD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $185.2M |
| Net Profit | $37.6M | $1.7M |
| Gross Margin | — | 85.7% |
| Operating Margin | — | 8.6% |
| Net Margin | 33.4% | 0.9% |
| Revenue YoY | 9.0% | 23.7% |
| Net Profit YoY | 33.0% | -88.5% |
| EPS (diluted) | $0.83 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $185.2M | ||
| Q3 25 | $115.7M | $169.1M | ||
| Q2 25 | $110.5M | $154.7M | ||
| Q1 25 | $103.1M | $125.2M | ||
| Q4 24 | $104.7M | $149.7M | ||
| Q3 24 | $101.8M | $141.5M | ||
| Q2 24 | $99.4M | $126.7M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | $1.7M | ||
| Q3 25 | $37.2M | $17.3M | ||
| Q2 25 | $30.1M | $-24.4M | ||
| Q1 25 | $28.2M | $-21.7M | ||
| Q4 24 | $30.3M | $14.7M | ||
| Q3 24 | $30.3M | $-6.7M | ||
| Q2 24 | $29.7M | $-15.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | 85.7% | ||
| Q3 25 | — | 88.5% | ||
| Q2 25 | — | 90.2% | ||
| Q1 25 | — | 90.7% | ||
| Q4 24 | — | 90.1% | ||
| Q3 24 | — | 90.6% | ||
| Q2 24 | — | 91.1% |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 8.6% | ||
| Q3 25 | 43.1% | 20.3% | ||
| Q2 25 | 35.2% | -6.1% | ||
| Q1 25 | 36.4% | -6.3% | ||
| Q4 24 | 38.6% | 10.7% | ||
| Q3 24 | 39.3% | 15.3% | ||
| Q2 24 | 40.4% | 11.8% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | 0.9% | ||
| Q3 25 | 32.1% | 10.2% | ||
| Q2 25 | 27.2% | -15.8% | ||
| Q1 25 | 27.4% | -17.3% | ||
| Q4 24 | 34.3% | 9.8% | ||
| Q3 24 | 29.8% | -4.8% | ||
| Q2 24 | 29.9% | -12.4% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.00 | ||
| Q3 25 | $0.82 | $0.06 | ||
| Q2 25 | $0.66 | $-0.08 | ||
| Q1 25 | $0.64 | $-0.07 | ||
| Q4 24 | $0.68 | $0.05 | ||
| Q3 24 | $0.69 | $-0.02 | ||
| Q2 24 | $0.68 | $-0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $293.5M |
| Total DebtLower is stronger | — | $392.7M |
| Stockholders' EquityBook value | $1.3B | $274.2M |
| Total Assets | $9.9B | $949.9M |
| Debt / EquityLower = less leverage | — | 1.43× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $293.5M | ||
| Q3 25 | $259.0M | $263.8M | ||
| Q2 25 | $218.3M | $231.0M | ||
| Q1 25 | $421.3M | $250.6M | ||
| Q4 24 | $563.1M | $249.9M | ||
| Q3 24 | $452.6M | $249.8M | ||
| Q2 24 | $730.5M | $260.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $392.7M | ||
| Q3 25 | — | $392.0M | ||
| Q2 25 | — | $391.3M | ||
| Q1 25 | — | $390.7M | ||
| Q4 24 | — | $390.1M | ||
| Q3 24 | — | $389.5M | ||
| Q2 24 | — | $388.9M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $274.2M | ||
| Q3 25 | $1.2B | $230.4M | ||
| Q2 25 | $1.2B | $204.3M | ||
| Q1 25 | $1.1B | $193.6M | ||
| Q4 24 | $1.1B | $194.0M | ||
| Q3 24 | $1.1B | $178.8M | ||
| Q2 24 | $1.0B | $132.5M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $949.9M | ||
| Q3 25 | $9.8B | $868.8M | ||
| Q2 25 | $9.7B | $815.3M | ||
| Q1 25 | $9.6B | $789.8M | ||
| Q4 24 | $9.5B | $785.0M | ||
| Q3 24 | $9.4B | $786.6M | ||
| Q2 24 | $9.6B | $749.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.43× | ||
| Q3 25 | — | 1.70× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | — | 2.02× | ||
| Q4 24 | — | 2.01× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 2.93× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $16.3M |
| Free Cash FlowOCF − Capex | — | $16.0M |
| FCF MarginFCF / Revenue | — | 8.6% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | — | 9.62× |
| TTM Free Cash FlowTrailing 4 quarters | — | $29.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $16.3M | ||
| Q3 25 | $38.3M | $35.7M | ||
| Q2 25 | $16.3M | $-26.5M | ||
| Q1 25 | $27.1M | $7.8M | ||
| Q4 24 | $175.2M | $-3.9M | ||
| Q3 24 | $19.8M | $-23.0M | ||
| Q2 24 | $40.1M | $22.7M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | $16.0M | ||
| Q3 25 | $38.0M | $35.3M | ||
| Q2 25 | $15.2M | $-28.9M | ||
| Q1 25 | $25.0M | $7.5M | ||
| Q4 24 | $171.2M | $-4.2M | ||
| Q3 24 | $19.1M | $-23.3M | ||
| Q2 24 | $39.4M | $21.6M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | 8.6% | ||
| Q3 25 | 32.8% | 20.9% | ||
| Q2 25 | 13.7% | -18.7% | ||
| Q1 25 | 24.3% | 6.0% | ||
| Q4 24 | 163.5% | -2.8% | ||
| Q3 24 | 18.8% | -16.5% | ||
| Q2 24 | 39.7% | 17.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.2% | ||
| Q3 25 | 0.3% | 0.2% | ||
| Q2 25 | 1.0% | 1.6% | ||
| Q1 25 | 2.0% | 0.2% | ||
| Q4 24 | 3.8% | 0.2% | ||
| Q3 24 | 0.6% | 0.3% | ||
| Q2 24 | 0.7% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | 9.62× | ||
| Q3 25 | 1.03× | 2.06× | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | -0.27× | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BY
Segment breakdown not available.
FOLD
| Other | $105.8M | 57% |
| Galafold | $64.8M | 35% |
| Pombiliti Opfolda | $14.6M | 8% |
